Research programme: Nogo receptor decoy - ReNetX Bio

Drug Profile

Research programme: Nogo receptor decoy - ReNetX Bio

Alternative Names: NgR(310)ecto-Fc

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University
  • Developer ReNetX Bio
  • Class Proteins
  • Mechanism of Action Myelin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Spinal cord injuries; Stroke
  • Research Glaucoma

Most Recent Events

  • 18 Oct 2017 ReNetX Bio in-licenses patents related to nogo receptor decoy programme from Yale University (ReNetX Bio pipeline, October 2017)
  • 18 Oct 2017 ReNetX Bio plans a proof of concept clinical trial for Spinal cord injuries in 2020 (ReNetX Bio pipeline, October 2017)
  • 16 Oct 2017 Early research in Glaucoma in USA (unspecified route) (ReNetX Bio pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top